R E Kast

Summary

Publications

  1. ncbi Borage oil reduction of rheumatoid arthritis activity may be mediated by increased cAMP that suppresses tumor necrosis factor-alpha
    R E Kast
    Department of Psychiatry, College of Medicine, University of Vermont, Burlington 05401, USA
    Int Immunopharmacol 1:2197-9. 2001
  2. ncbi Bupropion and chronic aphthous ulceration
    Richard E Kast
    Arch Dermatol 141:1167. 2005
  3. ncbi How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Bone Marrow Transplant 41:23-6. 2008
  4. ncbi Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Br J Neurosurg 26:813-7. 2012
  5. ncbi The rationale of targeting neutrophils with dapsone during glioblastoma treatment
    Richard E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Anticancer Agents Med Chem 11:756-61. 2011
  6. ncbi Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
    Johan Söderlund
    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    J Neuroinflammation 7:44. 2010
  7. ncbi Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone
    Richard E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    World J Biol Psychiatry 10:682-5. 2009
  8. ncbi Proposal for using small molecule tumor necrosis factor-alpha lowering agents, possibly bupropion, in aplastic anemia
    Richard E Kast
    University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    Med Hypotheses 65:374-6. 2005
  9. ncbi Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha
    Richard E Kast
    University of Vermont, Burlington, VT 05401, USA
    Arch Immunol Ther Exp (Warsz) 53:143-7. 2005
  10. ncbi Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma
    R E Kast
    University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    J Neurooncol 94:163-7. 2009

Detail Information

Publications48

  1. ncbi Borage oil reduction of rheumatoid arthritis activity may be mediated by increased cAMP that suppresses tumor necrosis factor-alpha
    R E Kast
    Department of Psychiatry, College of Medicine, University of Vermont, Burlington 05401, USA
    Int Immunopharmacol 1:2197-9. 2001
    ....
  2. ncbi Bupropion and chronic aphthous ulceration
    Richard E Kast
    Arch Dermatol 141:1167. 2005
  3. ncbi How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Bone Marrow Transplant 41:23-6. 2008
    ..Thus, lithium and sitagliptin enhance CXCL12 by different paths, potentially increasing trophic niche function. Awareness of this path is important in HSC transplantation...
  4. ncbi Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Br J Neurosurg 26:813-7. 2012
    ....
  5. ncbi The rationale of targeting neutrophils with dapsone during glioblastoma treatment
    Richard E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Anticancer Agents Med Chem 11:756-61. 2011
    ..Based on the available evidence summarized by the authors, dapsone has a strong theoretical potential to become a useful anti-VEGF, anti-angiogenic agent in glioblastoma treatment...
  6. ncbi Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
    Johan Söderlund
    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    J Neuroinflammation 7:44. 2010
    ....
  7. ncbi Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone
    Richard E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    World J Biol Psychiatry 10:682-5. 2009
    ....
  8. ncbi Proposal for using small molecule tumor necrosis factor-alpha lowering agents, possibly bupropion, in aplastic anemia
    Richard E Kast
    University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    Med Hypotheses 65:374-6. 2005
    ..Thus agents that lower TNF may be of benefit in AA. In preliminary studies we have found that the commonly used antidepressant bupropion lowers TNF. Thus, bupropion is a potential initial small molecule TNF inhibitor to consider for AA...
  9. ncbi Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha
    Richard E Kast
    University of Vermont, Burlington, VT 05401, USA
    Arch Immunol Ther Exp (Warsz) 53:143-7. 2005
    ..This paper suggests the use of bupropion in CLL to lower TNF levels, which may thereby slow CLL disease course...
  10. ncbi Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma
    R E Kast
    University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    J Neurooncol 94:163-7. 2009
    ..MA-MNTX combination should be tested as glioblastoma treatment adjunct. Temozolomide CSF levels are 10-20% of blood levels. Thus MA may also allow greater brain tissue temozolomide levels yet with lower systemic exposure...
  11. ncbi Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma
    Richard E Kast
    University of Vermont, Burlington, VT 05401, USA
    Cancer Biol Ther 7:1515-9. 2008
    ....
  12. ncbi Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP
    R E Kast
    Int J Immunopharmacol 22:1001-6. 2000
    ..TNF is a central mediator in several inflammatory diseases. Understanding TNF control systems will allow better delineation of pathophysiology and clinical care...
  13. ncbi Tiagabine may reduce bruxism and associated temporomandibular joint pain
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington 05401, USA
    Anesth Prog 52:102-4. 2005
    ..The doses used to suppress nocturnal bruxism at bedtime (4-8 mg) are lower than those used to treat seizures...
  14. ncbi Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Med Oncol 24:1-6. 2007
    ..This lowers intracellular cAMP levels. Lower cAMP results in lower Il-6 synthesis, lower levels of a required growth factor. Controlled studies are needed to define the role of COX inhibitors in melanoma treatment...
  15. ncbi Consideration of acamprosate for treatment of amyotrophic lateral sclerosis
    Richard E Kast
    Department of Psychiatry, University of Vermont, College of Medicine, 2 Church Street, Burlington, VT 05401, USA
    Med Hypotheses 69:836-7. 2007
    ....
  16. ncbi Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis
    Richard E Kast
    University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    Curr Stem Cell Res Ther 4:314-7. 2009
    ..If GBM stem cell function can be thwarted by potent aldehyde dehydrogenase inhibition, they will be less able to regenerate a stem cell derived tumor mass after primary resection or chemotherapy...
  17. ncbi Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Oncol Res 17:383-6. 2009
    ..Ambrisentan is a well-tolerated pill taken once daily. In theory, it should retard and inhibit lodgement and establishment of disseminated peritoneal micrometastases after debulking surgery...
  18. ncbi Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT, USA
    Br J Pharmacol 161:481-7. 2010
    ....
  19. ncbi Acarbose related diarrhea: increased butyrate upregulates prostaglandin E
    R E Kast
    Department of Psychiatry, College of Medicine, University of Vermont, Burlington 05401, USA
    Inflamm Res 51:117-8. 2002
    ..Despite these considerations, acarbose remains a safe medicine and may even have salutary intestinal consequences stemming from the same physiology as outlined here...
  20. ncbi Feedback between glial tumor necrosis factor-alpha and gp120 from HIV-infected cells helps maintain infection and destroy neurons
    Richard E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Neuroimmunomodulation 10:85-92. 2002
    ..Damaged neurons make factors that activate glia to upregulate TNF synthesis. These feedback cycles centering on gp120 and TNF contribute to HIV pathophysiology, neuron loss and maintenance of infection...
  21. ncbi Ribavirin in cancer immunotherapies: controlling nitric oxide helps generate cytotoxic lymphocyte
    R E Kast
    College of Medicine, University of Vermont, 2 Church St, Burlington, Vermont 05401, USA
    Cancer Biol Ther 1:626-30. 2002
    ..Tetrahydrobiopterin is an essential co-factor for all known isoforms of nitric oxide synthase. Lowered nitric oxide favors Th1 development as high levels favor Th2 weighting...
  22. ncbi Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function
    Richard E Kast
    College of Medicine, University of Vermont, Bington, VT 05401, USA Email
    Neoplasia 5:3-8. 2003
    ..Tetrahydrobiopterin is an essential cofactor for all known isoforms of nitric oxide synthase. Lowered nitric oxide favors Th1 development as high levels favor Th2 weighting...
  23. ncbi Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation
    R E Kast
    College of Medicine, University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    Mol Immunol 40:297-303. 2003
    ..Therefore, zileuton, an orally active 5-lipooxygenase inhibitor that prevents leukotriene synthesis, should be added whenever profound COX inhibition is undertaken in cancer immunotherapies...
  24. ncbi Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Br J Pharmacol 164:1393-6. 2011
    ..Clinical assessment of the potential benefit of such combined therapy against glioblastoma is warranted...
  25. ncbi Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT, USA
    Gen Hosp Psychiatry 25:495-6. 2003
  26. ncbi Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    J Clin Pharm Ther 35:657-63. 2010
    ..The anti-HIV drug, maraviroc, inhibits human CCR5's ligand from binding, and hence blocks CCR5 stimulation. The anti-nausea drug aprepitant blocks substance P signaling at NK-1R...
  27. ncbi Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct
    Richard E Kast
    University of Vermont, Psychiatry, Burlington, VA, USA
    Turk Neurosurg 20:425-9. 2010
    ..These three drugs used simultaneously are potential low morbidity paths to deeply inhibit CXCR4/CXCL12 signaling during cytotoxic glioblastoma treatment...
  28. ncbi Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir
    R E Kast
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Hematol Oncol 25:96-7. 2007
    ..We suggest that currently marketed anti-viral protease inhibitors be investigated in animal models of doxorubicin cardiomyopathy and if such studies do indeed show protection, human studies be initiated...
  29. ncbi Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects
    R E Kast
    University of Vermont Psychiatry, Burlington, VT 05401, USA
    Eur J Cancer Care (Engl) 16:351-4. 2007
    ..Multiple clinical and economic advantages of mirtazapine and olanzapine over currently used 'setron class medicines are reviewed. Double-blind studies against the 'setron class drugs are warranted...
  30. ncbi Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2
    Richard E Kast
    Department of Psychiatry, University of Vermont, 2 Church Street, Burlington, VT 05401, United States
    Med Hypotheses 67:1389-90. 2006
    ....
  31. ncbi Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha
    R E Kast
    University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    Inflammopharmacology 14:256-9. 2006
    ....
  32. ncbi Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropion
    R E Kast
    University of Vermont, School of Medicine, Department of Psychiatry, Burlington, VT 05401, USA
    Leuk Res 29:1459-63. 2005
    ..Early data indicates that the common generic antidepressant bupropion may ameliorate Crohn's disease course by down regulating TNF synthesis, maybe it will slow the course of MM as well...
  33. ncbi Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma
    Richard E Kast
    Department of Psychiatry, College of Medicine, University of Vermont, 2 Church Street, Burlington, VT 04501, USA
    Med Hypotheses 62:817-8. 2004
    ....
  34. ncbi Bupropion for Blau syndrome
    Eric Lewin Altschuler
    Department of Psychiatry, University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    Med Hypotheses 62:297-8. 2004
    ..We are not aware of any cure or specific treatment for BS. We have found that bupropion is effective for CD, and we now suggest that bupropion be considered for treatment of BS...
  35. ncbi Bupropion: pharmacology and therapeutic applications
    Kevin F Foley
    University of Vermont, Department of Medical Laboratory and Radiation Sciences Burlington, 302 Rowell Building, VT 05405, USA
    Expert Rev Neurother 6:1249-65. 2006
    ..Anecdotal reports indicate bupropion may lower inflammatory mediators such as tumor necrosis factor-alpha, may lower fatigue in cancer and may help reduce concentration problems...
  36. ncbi Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin's lymphoma allowing cytotoxicity by acyclovir
    Richard E Kast
    University of Vermont, 2 Church Street, Burlington, VT 05401, USA
    Yonsei Med J 47:287-90. 2006
    ....
  37. ncbi Consideration of use of phenothiazines in particular trifluorperazine for epidermal growth factor receptor associated cancers
    Richard E Kast
    Department of Psychiatry, College of Medicine, University of Vermont, 2 Church Street, Burlington, VT 05401, United States
    Med Hypotheses 69:1074-5. 2007
    ....
  38. ncbi Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion
    Richard E Kast
    J Hepatol 39:131-3. 2003
  39. ncbi Crohn's disease remission on bupropion
    Susie Kane
    Gastroenterology 125:1290. 2003
  40. ncbi Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha?
    Eric Lewin Altschuler
    Psychosom Med 65:719. 2003
  41. ncbi Paroxetine for hepatopulmonary syndrome?
    Eric Lewin Altschuler
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Med Hypotheses 62:446-7. 2004
    ..We therefore suggest that, the extremely safe and commonly used antidepressant medication paroxetine (Paxil) which is a potent nitric oxide synthase (NOS) inhibitor be considered for use in HPS...
  42. ncbi Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease
    Ajay Bhatia
    J Rheumatol 34:447-9; author reply 449-50. 2007
  43. ncbi Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis
    Eric Lewin Altschuler
    Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1240, New York, NY 10029, USA
    Med Hypotheses 64:118-9. 2005
    ....
  44. ncbi H1-antihistamines
    Eric L Altschuler
    N Engl J Med 352:1155-7; author reply 1155-7. 2005
  45. ncbi Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression
    Eric Lewin Altschuler
    Mt Sinai School of Medicine, 1425 Madison Avenue, Box 1240, NY 10029, USA
    Med Hypotheses 65:65-7. 2005
    ....
  46. ncbi Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy
    Eric Lewin Altschuler
    Kidney Int 68:2910-1. 2005
  47. ncbi Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists
    Richard E Kast
    Neoplasia 9:689. 2007
  48. ncbi Intraperitoneal lavage with imiquimod to eliminate epithelial ovarian cancer micro metastases
    Richard E Kast
    Med Hypotheses 70:1223-4. 2008